Envestnet Asset Management Inc. Has $144,000 Holdings in Evolent Health, Inc. (NYSE:EVH)

Envestnet Asset Management Inc. trimmed its stake in shares of Evolent Health, Inc. (NYSE:EVH) by 82.6% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 12,801 shares of the technology company’s stock after selling 60,709 shares during the period. Envestnet Asset Management Inc.’s holdings in Evolent Health were worth $144,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Pilgrim Partners Asia Pte Ltd acquired a new stake in shares of Evolent Health in the 4th quarter valued at about $26,000. R Squared Ltd acquired a new stake in Evolent Health in the 4th quarter valued at approximately $31,000. AlphaQuest LLC lifted its stake in Evolent Health by 21,650.0% in the 4th quarter. AlphaQuest LLC now owns 3,045 shares of the technology company’s stock valued at $34,000 after acquiring an additional 3,031 shares in the last quarter. Parkside Financial Bank & Trust boosted its position in Evolent Health by 90.7% during the 4th quarter. Parkside Financial Bank & Trust now owns 4,957 shares of the technology company’s stock worth $56,000 after acquiring an additional 2,358 shares during the last quarter. Finally, AlphaCentric Advisors LLC bought a new position in shares of Evolent Health during the 4th quarter worth approximately $61,000.

Insider Buying and Selling at Evolent Health

In other Evolent Health news, CEO Seth Blackley purchased 55,225 shares of the firm’s stock in a transaction that occurred on Thursday, March 6th. The shares were acquired at an average cost of $9.01 per share, for a total transaction of $497,577.25. Following the completion of the purchase, the chief executive officer now owns 762,217 shares of the company’s stock, valued at approximately $6,867,575.17. The trade was a 7.81 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Diane Holder acquired 2,735 shares of the company’s stock in a transaction on Thursday, March 6th. The stock was acquired at an average price of $9.33 per share, with a total value of $25,517.55. Following the purchase, the director now directly owns 70,584 shares in the company, valued at approximately $658,548.72. This represents a 4.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have bought a total of 74,000 shares of company stock valued at $666,315 in the last ninety days. 1.60% of the stock is currently owned by corporate insiders.

Evolent Health Stock Performance

NYSE EVH opened at $10.77 on Friday. Evolent Health, Inc. has a 52-week low of $8.35 and a 52-week high of $33.63. The stock has a market cap of $1.26 billion, a PE ratio of -13.13 and a beta of 1.04. The firm has a 50-day moving average of $9.60 and a 200-day moving average of $11.72. The company has a debt-to-equity ratio of 0.58, a quick ratio of 1.04 and a current ratio of 1.04.

Evolent Health (NYSE:EVH) last issued its quarterly earnings data on Thursday, February 20th. The technology company reported $0.03 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.38 by ($0.35). The firm had revenue of $646.54 million for the quarter, compared to the consensus estimate of $650.92 million. Evolent Health had a positive return on equity of 5.73% and a negative net margin of 2.41%. On average, sell-side analysts anticipate that Evolent Health, Inc. will post 0.08 EPS for the current year.

Analyst Ratings Changes

A number of brokerages have recently commented on EVH. UBS Group cut their price objective on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a research report on Thursday, January 16th. JMP Securities restated a “market outperform” rating and set a $13.00 price objective on shares of Evolent Health in a research note on Monday, April 28th. Canaccord Genuity Group lowered their price target on Evolent Health from $23.00 to $16.00 and set a “buy” rating on the stock in a research report on Thursday, January 23rd. Oppenheimer cut their price objective on Evolent Health from $28.00 to $18.00 and set an “outperform” rating for the company in a report on Friday, January 24th. Finally, Citigroup lowered their target price on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, January 10th. One research analyst has rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company. According to MarketBeat, the company has an average rating of “Buy” and a consensus price target of $17.71.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.